Chatterjee S K, Qin H, Manna S, Tripathi P K
Department of Internal Medicine, Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536, USA.
Anticancer Res. 1999 Jul-Aug;19(4B):2869-73.
The efficacy of a recombinant vaccinia virus (rvv-GM-CSF) expressing the granulocyte macrophage colony stimulating factor (GM-CSF) as tumor vaccine was evaluated in the murine B16-F10 melanoma model. The vaccine was prepared by infection of irradiated tumor cells with rvv-GM-CSF. Control vaccine was B-16 cells infected with a recombinant vaccinia virus expressing Escherichia coli beta-galactosidase (rvv-lacZ). Pre-vaccination of naive C57BL/6 mice later inoculated with tumor cells and treatment of mice bearing tumors with GM-CSF vaccine inhibited tumor development and prolonged survival. Lung metastasis of B-16 was also inhibited by treatment with GM-CSF vaccine. The vaccine effects appeared to be tumor cell specific. The efficacy of the vaccine was comparable to a retroviral vaccine (MFG-muGM-CSF) in this system. The vaccine was also effective when rvv-GM-CSF was directly injected into the tumor. These data suggest that this vaccine approach has potential for use in cancer treatment, especially for patients with easily accessible tumors.
在小鼠B16-F10黑色素瘤模型中评估了表达粒细胞巨噬细胞集落刺激因子（GM-CSF）的重组痘苗病毒（rvv-GM-CSF）作为肿瘤疫苗的疗效。该疫苗通过用rvv-GM-CSF感染经辐照的肿瘤细胞制备。对照疫苗是用表达大肠杆菌β-半乳糖苷酶的重组痘苗病毒（rvv-lacZ）感染的B-16细胞。预先接种未感染肿瘤细胞的C57BL/6小鼠，并用GM-CSF疫苗治疗荷瘤小鼠，可抑制肿瘤发展并延长生存期。GM-CSF疫苗治疗也可抑制B-16的肺转移。疫苗效果似乎具有肿瘤细胞特异性。在该系统中，该疫苗的疗效与逆转录病毒疫苗（MFG-muGM-CSF）相当。当将rvv-GM-CSF直接注射到肿瘤中时，该疫苗也有效。这些数据表明，这种疫苗方法具有用于癌症治疗的潜力，特别是对于肿瘤易于接近的患者。
